Loranne Agius
Overview
Explore the profile of Loranne Agius including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ford B, Chachra S, Alshawi A, Oakley F, Fairclough R, Smith D, et al.
Biochem Pharmacol
. 2024 Aug;
229():116499.
PMID: 39173844
Glucokinase activators (GKAs) have been developed as blood glucose lowering drugs for type 2 diabetes. Despite good short-term efficacy, several GKAs showed a decline in efficacy chronically during clinical trials....
2.
Buziau A, Oosterveer M, Wouters K, Bos T, Tolan D, Agius L, et al.
Mol Metab
. 2024 Jul;
87:101984.
PMID: 38972375
Objective: Stable isotope studies have shown that hepatic de novo lipogenesis (DNL) plays an important role in the pathogenesis of intrahepatic lipid (IHL) deposition. Furthermore, previous research has demonstrated that...
3.
Ford B, Chachra S, Rodgers K, Moonira T, Al-Oanzi Z, Anstee Q, et al.
Mol Metab
. 2023 Apr;
72:101722.
PMID: 37031802
Objectives: The Glucokinase Regulatory Protein GKRP, encoded by GCKR, enables acute regulation of liver glucokinase to support metabolic demand. The common human GCKR rs1260326:Pro446 > Leu variant within a large...
4.
Agius L, Chachra S, Ford B
Front Endocrinol (Lausanne)
. 2020 Dec;
11:594041.
PMID: 33281747
The Carbohydrate response element binding protein, ChREBP encoded by the gene, is a transcription factor that is expressed at high levels in the liver and has a prominent function during...
5.
Leitch A, Abdelghany T, Charlton A, Grigalyte J, Oakley F, Borthwick L, et al.
Ecotoxicol Environ Saf
. 2020 Jul;
202:110902.
PMID: 32634706
The ionic liquid 1-octyl-3-methylimidazolium (M8OI) has been found in the environment and identified as a hazard for triggering the liver disease primary biliary cholangitis (PBC). Given limited toxicity data for...
6.
Ford B, Chachra S, Alshawi A, Brennan A, Harnor S, Cano C, et al.
Diabetes Obes Metab
. 2020 Jun;
22(11):1985-1994.
PMID: 32519798
Aim: To test the hypothesis that glucokinase activators (GKAs) induce hepatic adaptations that alter intra-hepatocyte metabolite homeostasis. Methods: C57BL/6 mice on a standard rodent diet were treated with a GKA...
7.
Agius L, Ford B, Chachra S
Int J Mol Sci
. 2020 May;
21(9).
PMID: 32375255
Metformin therapy lowers blood glucose in type 2 diabetes by targeting various pathways including hepatic gluconeogenesis. Despite widespread clinical use of metformin the molecular mechanisms by which it inhibits gluconeogenesis...
8.
Moonira T, Chachra S, Ford B, Marin S, Alshawi A, Adam-Primus N, et al.
J Biol Chem
. 2020 Jan;
295(10):3330-3346.
PMID: 31974165
The chronic effects of metformin on liver gluconeogenesis involve repression of the gene, which is regulated by the carbohydrate-response element-binding protein through raised cellular intermediates of glucose metabolism. In this...
9.
Barr D, Szennyes E, Bokor E, Al-Oanzi Z, Moffatt C, Kun S, et al.
ACS Chem Biol
. 2019 Jun;
14(7):1460-1470.
PMID: 31243960
Several -β-d-glucopyranosyl azoles have recently been uncovered as among the most potent glycogen phosphorylase (GP) catalytic site inhibitors discovered to date. Toward further exploring their translational potential, experiments have been...
10.
Alshawi A, Agius L
J Biol Chem
. 2018 Dec;
294(8):2839-2853.
PMID: 30591586
The mechanisms by which metformin (dimethylbiguanide) inhibits hepatic gluconeogenesis at concentrations relevant for type 2 diabetes therapy remain debated. Two proposed mechanisms are 1) inhibition of mitochondrial Complex 1 with...